Axovant: Fiscal Q1 Earnings Snapshot
LONDON (AP) _ Axovant Sciences Ltd. (SIOX) on Thursday reported a loss of $11.9 million...
Stay updated with breaking news from Axovant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LONDON (AP) _ Axovant Sciences Ltd. (SIOX) on Thursday reported a loss of $11.9 million...
Axovant: Fiscal Q4 Earnings Snapshot by The Associated Press Last Updated Jun 9, 2021 at 7:28 am EDT NEW YORK (AP) _ Axovant Sciences Ltd. (SIOX) on Wednesday reported a loss of $3.3 million in its fiscal fourth quarter. On a per-share basis, the New York-based company said it had a loss of 5 cents. Losses, adjusted for non-recurring gains, came to 19 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share. For the year, the company reported that its loss narrowed to ...
Dive Brief: Roivant Sciences, an unusual holding company with roughly a dozen biotech subsidiaries, will go public through a merger with a blank-check entity in a deal that values the company at $7.3 billion. Roivant will get $611 million in cash by merging with Montes Archimedes Acquisition Corp., a special purpose acquisition company, or SPAC, formed by Patient Square Capital. That figure includes $411 million already in a Montes Archimedes Trust and a commitment by Patient Square and other investors to buy $200 million in Roivant stock at $10 apiece. The agreement will leave Roivant, whose...
Share this article LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight's " Parkinson's Disease Market" report provides a thorough comprehension of the Parkinson's Disease, historical and forecasted epidemiology, and the Parkinson's Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Parkinson's Disease market report also proffers an analysis of the current Parkinson's Disease treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. Key takeaways of the The increase in Parkinson 's di...
(1) Centessa Pharmaceuticals ("Centessa"), a pharmaceutical company consisting of 10 subsidiary companies advancing a portfolio of high conviction programs with strong biological validation, today announced key additions to its leadership team. Gregory Weinhoff, M.D., MBA, joined the team as chief financial officer, while Mary Lynne Hedley, Ph.D., Robert M. Califf, M.D., MACC, and Samarth Kulkarni, Ph.D., joined Centessa's board of directors effective February 23, 2021. "Centessa launched last month with a goal of redefining pharmaceutical R&D productivity through an asset-centric model that ...